Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia.
Journal Information
Full Title: Blood Adv
Abbreviation: Blood Adv
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"Conflict-of-interest disclosure: D.J.D. has served as a consultant for Amgen, Autolos, Agios, Blueprint, Forty-Seven, Gilead, Incyte, Jazz, Novartis, Pfizer, Servier, and Takeda; and declares research funding from 10.13039/100006483AbbVie, Glycomimetics, 10.13039/100004336Novartis, and Blueprint Pharmaceuticals; M.R.L. receives research support from 10.13039/100006483AbbVie and 10.13039/100004336Novartis. S.S. declares no competing financial interests."
Funding Disclosure
Evidence found in paper:
"This work was supported by the Foley Family Fellowship Fund."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025